Marc Scheineson News Today

FDA Commissioner Robert Califf said Thursday that misinformation, what he sees as one of the biggest issues facing his agency’s many jurisdictions, needs an equally expansive, overlapping approach.

The slew of cases has alarmed legal experts, patient advocates and former health officials from both parties who say the consequences for the health care system — from drugmakers to nurses to patients — could be dire.

The slew of cases has alarmed legal experts, patient advocates and former health officials from both parties who say the consequences for the health care system — from drugmakers to nurses to patients — could be dire.

The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease. The deadly neurological disease has few treatment options. NurOwn, a stem cell therapy,

The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease. The deadly neurological disease has few treatment options. NurOwn, a stem cell therapy,

WASHINGTON (AP) — The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by

The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease. The deadly neurological disease has few treatment options. NurOwn, a stem cell therapy,

The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease. The deadly neurological disease has few treatment options. NurOwn, a stem cell therapy, is at the center of a yearslong lobbying campaign by patients seeking access to experimental medicines. But the FDA has repeatedly rebuffed drugmaker Brainstorm. The agency says the company's only study failed to show a benefit for patients. The review is the starkest test yet of FDA's c...

The Food and Drug Administration is considering a much-debated new treatment for Lou Gehrig’s disease, a deadly neurological disease that has few treatment options.

The Food and Drug Administration is considering a much-debated new treatment for Lou Gehrig’s disease, a deadly neurological disease that has few treatment options.